Horizon Therapeutics plc, announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED,...
Horizon Therapeutics plc announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment...
Horizon Therapeutics plc announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of...
